

Supplemental Tables for:
High Proliferation Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Early Breast Cancer
Emilio Alba Conejo et al.

Table S1. Univariate analysis for factors associated to pCR in breast and axilla. The table summarizes the individual association of different variables with the pCR by logistic regression univariate analysis. a) Significant p-values and 95%CI are indicated in bold. b) Reference value; c) TNM staging to define breast cancer by The American Joint Committee on Cancer (AJCC). CI, Confidence interval, EC-D, epirubicin plus cyclophosphamide followed by docetaxel; ER, estrogen receptors; EC-DCb, EC-D plus carboplatin; EC-DL, EC-D plus lapatinib; EC-DH, EC-D plus trastuzumab; GAT, gemcitabine, adriamycin, and paclitaxel; MDH, Myocet™, docetaxel, and trastuzumab; OR, Odds ratio; PR, progesterone receptors.

	<i>P-value</i> ^a	OR (95%CI)
Treatment	0.0023	
EC-D ^b		
EC-DCb	0.1765	2.593 (1.077 – 6.239)
EC-DL	0.5829	2.037 (0.812 – 5.111)
EC-DH	0.0008	4.750 (1.999 – 11.285)
GAT	0.0159	0.484 (0.128 – 1.823)
MDH	0.6906	1.957 (0.739 – 5.181)
Age	0.4166	1.010 (0.986 – 1.035)
Menopausal status	0.2613	1.372 (0.790 – 2.383)
Posmenopausal (vs. Premenopausal)		
Tumor size (continuous)	0.0368	0.870 (0.763 – 0.991)
Tumor size ^c	0.2982	
T1 ^b		
T2	0.8374	0.581 (0.222 – 1.520)
T3	0.1603	0.368 (0.125 – 1.084)
T4	0.5764	0.441 (0.116 – 1.684)
Nodal status ^a	0.4085	
N0 ^b		
N1	0.3215	1.499 (0.824 – 2.724)
N2	0.9433	1.182 (0.419 – 3.337)
Histologic grade	0.0185	
G1 ^b		
G2	0.7312	2.368 (0.507 – 11.066)
G3,	0.0056	5.467 (1.217 – 24.563)
GX	0.3753	3.636 (0.689 – 19.194)
ER negative (vs. positive)	<0.0001	4.883 (2.604 – 9.157)
PR negative (vs. positive)	<0.0001	5.218 (2.582 – 10.547)
HER2 positive (vs. negative)	0.0041	2.267 (1.296 – 3.968)

	<i>P-value</i> ^a	OR (95%CI)
Subtypes (ER/HER2 status)	0.0002	
ER+ HER2+ ^b		
ER+ HER2-	0.0004	0.046 (0.006 – 0.361)
ER- HER2+	<0.0001	3.013 (1.354 – 6.702)
ER- HER2-	0.0062	1.687 (0.804 – 3.539)
Ki67 expression	<0.0001	1.022 (1.011 – 1.032)
Ki67>50% (vs. Ki67≤50%)	0.0005	2.737 (1.554 – 4.823)

^a p-values and 95%CI in bold are statistically significant.

^b Reference value

^c TNM staging to define breast cancer by The American Joint Committee on Cancer (AJCC).

CI, Confidence interval, EC-D, epirubicin plus cyclophosphamide followed by docetaxel; ER, estrogen receptors; EC-DCb, EC-D plus carboplatin; EC-DL, EC-D plus lapatinib; EC-DH, EC-D plus trastuzumab; GAT, gemcitabine, adriamycin, and paclitaxel; MDH, Myocet™, docetaxel, and trastuzumab; OR, Odds ratio; PR, progesterone receptors

Table S2. Multivariate analyses for factors associated to pCR in breast and axilla in the ER-HER2 and ER-HER2+ subpopulation. The table summarizes the logistic regression multivariate analyses in the ER-patient subgroup, those with the highest rates of pCR. pCR indicates pathologic complete response in breast and axilla. AUC indicates area under the curve.

	OR	95% CI	P-value
Ki67>50 (vs. Ki67≤50%)	3.026	1.184 – 7.734	0.0208
HER2 positive (vs. HER2 negative)	3.390	1.317 – 8.726	0.0114

AUC=0.6178

Table S3. List of participating institutions in the GEICAM/2002-01, GEICAM/2003-03, GEICAM 2006-03 and GEICAM/2006-14.

Hospital Clínico Universitario de Valencia, Valencia, Spain
Hospital Virgen de la Victoria, Málaga, Spain
Hospital Miguel Servet, Zaragoza, Spain
Complejo Hospitalario de Jaén, Jaén, Spain
Hospital del Mar, Barcelona, Spain
Complejo Hospitalario Universitario A Coruña, La Coruña, Spain
Hospital Virgen de la Salud, Toledo, Spain
Instituto Valenciano de Oncología, Valencia, Spain
Hospital Reina Sofía, Córdoba, Spain
Consorci Sanitari Parc Taulí, Sabadell, Spain
Hospital Germans Trias i Pujol, Badalona, Spain
Onkologikoa, San Sebastián, Spain
Hospital Santa Creu i Sant Pau, Barcelona, Spain
Althaia Xarxa Assistencial de Manresa, Manresa, Spain
Consorci Sanitari de Terrassa, Terrassa, Spain
Centro oncologico de Galicia, La Coruña, Spain
Hospital Clinic i Provincial, Barcelona, Spain
Hospital La Fe, Valencia, Spain
Hospital Madrid Norte - Sanchinarro (CIOCC), Madrid, Spain
Hospital de la Princesa, Madrid, Spain
Hospital de Torrevieja, Torrevieja, Spain
Hospital Mutua de Terrassa, Terrassa, Spain
Hospital Infanta Cristina, Badajoz, Spain
Institut Català d'Oncologia de Barcelona, Barcelona, Spain
Hospital General de Granollers, Granollers, Spain
Hospital Marqués de Valdecilla, Santander, Spain
Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain
Hospital Ramón y Cajal, Madrid, Spain
Fundación Hospitalaria de Alcorcón, Alcorcón, Spain
Hospital Puerta del Mar, Cádiz, Spain
Complejo Hospitalario Xeral Calde, Lugo, Spain
Hospital Lozano Blesa, Zaragoza, Spain
Hospital Virgen de los Lirios, Alcoy, Spain
Hospital General de Valencia, Valencia, Spain